TY - JOUR
T1 - Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer
AU - Narita, Shintaro
AU - Nomura, Kyoko
AU - Hatakeyama, Shingo
AU - Takahashi, Masahiro
AU - Sakurai, Toshihiko
AU - Kawamura, Sadafumi
AU - Hoshi, Senji
AU - Ishida, Masanori
AU - Kawaguchi, Toshiaki
AU - Ishidoya, Shigeto
AU - Shimoda, Jiro
AU - Sato, Hiromi
AU - Mitsuzuka, Koji
AU - Tochigi, Tatsuo
AU - Tsuchiya, Norihiko
AU - Ohyama, Chikara
AU - Arai, Yoichi
AU - Nagashima, Kengo
AU - Habuchi, Tomonori
N1 - Funding Information:
We express our appreciation to Yoko Mitobe, Yukiko Sugiyama, and Saeko Nakamura for their assistance in performing this study. This study was supported in part by research grants from the MEXT/JSPS (19K09663).
Publisher Copyright:
© 2019, The Author(s).
PY - 2019/12/1
Y1 - 2019/12/1
N2 - We evaluated the impact of early changes in serum biomarker levels on the survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who were initially treated with androgen deprivation therapy (ADT). We retrospectively investigated 330 patients with mHSPC whose serum maker levels were at baseline and at 2–4 months. An optimal Cox regression model was established with the highest optimism-corrected concordance index based on 10-fold cross-validation. The median cancer-specific survival (CSS) and overall survival (OS) were 7.08 and 6.47 years (median follow-up, 2.53 years), respectively. In the final optimal Cox model with serum biomarker levels treated as time-varying covariates, prostate-specific antigen (PSA), hemoglobin (Hb), and alkaline phosphatase (ALP) significantly increased the risk of poor survival in the context of both CSS and OS. Kaplan–Meier curves stratified by the three risk factors of high PSA, low Hb and high ALP desmondtated that median OS were not reached with none of these factors, 6.47 years with one or two factors, and 1.76 years with all three factors.Early changes in serum biomarker levels after ADT may be good prognostic markers for the survival of patients with mHSPC.
AB - We evaluated the impact of early changes in serum biomarker levels on the survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who were initially treated with androgen deprivation therapy (ADT). We retrospectively investigated 330 patients with mHSPC whose serum maker levels were at baseline and at 2–4 months. An optimal Cox regression model was established with the highest optimism-corrected concordance index based on 10-fold cross-validation. The median cancer-specific survival (CSS) and overall survival (OS) were 7.08 and 6.47 years (median follow-up, 2.53 years), respectively. In the final optimal Cox model with serum biomarker levels treated as time-varying covariates, prostate-specific antigen (PSA), hemoglobin (Hb), and alkaline phosphatase (ALP) significantly increased the risk of poor survival in the context of both CSS and OS. Kaplan–Meier curves stratified by the three risk factors of high PSA, low Hb and high ALP desmondtated that median OS were not reached with none of these factors, 6.47 years with one or two factors, and 1.76 years with all three factors.Early changes in serum biomarker levels after ADT may be good prognostic markers for the survival of patients with mHSPC.
UR - http://www.scopus.com/inward/record.url?scp=85070824415&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070824415&partnerID=8YFLogxK
U2 - 10.1038/s41598-019-48600-8
DO - 10.1038/s41598-019-48600-8
M3 - Article
C2 - 31427687
AN - SCOPUS:85070824415
VL - 9
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
IS - 1
M1 - 12071
ER -
